Skip to main
ADPT

Adaptive Biotechnologies (ADPT) Stock Forecast & Price Target

Adaptive Biotechnologies (ADPT) Analyst Ratings

Based on 9 analyst ratings
Buy
Strong Buy 56%
Buy 33%
Hold 11%
Sell 0%
Strong Sell 0%

Bulls say

Adaptive Biotechnologies Corp is positioned for strong financial growth, driven by improvements in clinical average selling prices (ASP) and a favorable clinical mix shift. The transition to the NovaSeq X platform is anticipated to increase sequencing margins, supporting the overall gross profit outlook for the company. Furthermore, the expected growth in minimal residual disease (MRD) diagnostics, alongside rising ASPs and incremental volume increases, is projected to enhance both top-line revenue and gross margins significantly by 2025.

Bears say

Adaptive Biotechnologies is facing a stagnant revenue outlook in its Immune Medicine division, as no growth value is anticipated while the company works to generate interest in its TCR-Antigen model and develop its autoimmunity program. A concerning statistic indicates that approximately 25% of patients receiving an ID test do not obtain a minimal residual disease (MRD) result within the subsequent 12 months, potentially hindering the frequency of average tests conducted. Despite being a leader in the market, the company is grappling with significant challenges that may limit its growth potential in the near future.

Adaptive Biotechnologies (ADPT) has been analyzed by 9 analysts, with a consensus rating of Buy. 56% of analysts recommend a Strong Buy, 33% recommend Buy, 11% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Adaptive Biotechnologies and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Adaptive Biotechnologies (ADPT) Forecast

Analysts have given Adaptive Biotechnologies (ADPT) a Buy based on their latest research and market trends.

According to 9 analysts, Adaptive Biotechnologies (ADPT) has a Buy consensus rating as of Jan 28, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $16.67, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $16.67, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Adaptive Biotechnologies (ADPT)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.